A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
Purpose
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.1 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
Conditions
- SARS-CoV2
- COVID-19
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Adults 18 years of age and above, at time of screening. 2. Completed primary approved/authorized COVID-19 vaccination series with ≥ 2 mRNA vaccine doses. 3. Last COVID-19 vaccine received ≥6 months prior to study vaccination. 4. Male and female participants of childbearing potential must agree to consistently use a highly effective method of contraception from at least 30 days prior to enrollment and through 3 months after the last study vaccination. 5. Is medically stable, as determined by the site investigator (based on review of health status, vital signs, medical history, and physical examination) with screening lab values within normal limits or abnormalities assessed as not clinically significant. 6. Agree to not participate in any other SARS-CoV-2 infection prevention trial (vaccine, drug, biologic, PrEP) during participation in the study. 7. Willing and able to provide informed consent prior to initiation of study procedures. 8. Available for all study visits, willing to participate in all study procedures, and not planning to relocate from the area for the duration of the study. 9. Negative rapid molecular Covid test at the screening visit and on Day 1 prior to vaccine dosing.
Exclusion Criteria
- Participant has an acute illness as defined by any of the following (note: assessment may be repeated once during screening period): a. As determined by the site investigator, within 72 hours prior to vaccination. i. An acute illness that is nearly resolved, with only minor residual symptoms remaining, is allowable if, in the opinion of the site investigator, the residual symptoms will not interfere with the ability of study staff to assess safety parameters as required by the protocol. b. Presence of a fever ≥ 38.0°C (100.4°F) measured orally at baseline, on Day 1 prior to vaccination. c. Receipt of antipyretic/analgesic medications within 24 hours prior to vaccine administration. 2. Participant has had a positive COVID test within 90 days prior to screening. 3. Current or planned participation in any other interventional clinical trial. 4. Participation in research involving any investigational product within 45 days prior to study vaccination. 5. Receipt of any approved or authorized products intended to prevent SARS-CoV2 infection within 6 months prior to study vaccination. 6. Receipt or donation of blood products or immunoglobulins within 60 days prior to enrollment or planned administration during the study. 7. Received influenza vaccination within 14 days prior to study vaccination, or any other vaccine within 30 days prior to study vaccination. 8. Any autoimmune or immunodeficiency disease/condition (including and not limited to untreated or advanced HIV infection with CD4 counts <200 cells/mm^3, history of AIDS defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV, severe combined immunodeficiency (SCID), hypogammaglobulinemia, asplenia or functional asplenia). 9. Unstable medical or psychiatric illness (acute or chronic illness) requiring significant medical monitoring and intervention during the 90 days prior to enrollment. Note: diabetes mellitus (Types 1 & 2) are not excluded if assessed by the principal investigator (PI) as well-controlled. 10. Administration of immunosuppressants, systemic glucocorticoids, or other immune-modifying drugs within the following timeframes: 1. B-cell therapies within the 6 months prior to first study vaccination 2. Prednisone, ≥20 mg for more than 2 weeks, within the 30 days prior to study vaccination 3. Other medications in this category, including but not limited to high-dose inhaled corticosteroids (>800 mcg/day of beclomethasone dipropionate or equivalent); antimetabolites; transplant immunosuppressive agents; alkylating agents; cell-depleting agents; or cancer chemotherapeutics, within the 90 days prior to study vaccination. 4. Any medication for any period of time that, in the opinion of the site investigator, could impede immune response to vaccination. 5. Use of any dose montelukast OR inhaled, intranasal, intra-articular, or systemic corticosteroids within 2 weeks prior to study vaccination. 6. Planned use of any of these medications during the study. 11. Known contraindication to IM injection or blood draws (e.g. bleeding diathesis, acquired coagulopathy, significant bleeding or bruising) or to oral route of administration (unable to swallow tablets). 12. Any known allergies to components contained in the investigational product (including fish gelatin) or comparator or latex allergy (including polyethylene glycol [PEG] allergies) and/or history of serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain. 13. Women who are pregnant (pregnancy tests will be performed at screening and prior to dosing), breastfeeding, or who plan to become pregnant during the study. 14. History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine. Such conditions may include but are not limited to: a. Any history of: i. GI malignancy ii. malabsorption iii. pancreatobiliary disorders iv. inflammatory bowel disease v. irritable bowel disease vi. hiatal hernia vii. surgical resection b. History of diagnosis or treatment in past 5 years of: i. esophageal or gastric motility disorder ii. gastroesophageal reflux disorder iii. peptic ulcer iv. cholecystectomy. 15. Use of antibiotics, proton pump inhibitors, H2 blockers, or antacids within 7 days prior to study drug administration or planned use during the study. 16. Use of drugs known to affect gastrointestinal motility including glucagon-like peptide 1 (GLP-1) receptor agonists including tirzepatide (Mounjaro) and semaglutide (Wegovy, Ozempic) within 30 days prior to drug administration. 17. Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug administration or planned use during the study. 18. Personal or familial history of hypercoagulable states to include personal past history of deep vein thrombosis (DVT). 19. Personal history of myocarditis or pericarditis. 20. Positive Hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody at the screening visit. 21. History of drug, alcohol, or chemical abuse within 1 year of screening. 22. Positive urine drug screen for drugs of abuse at screening (except for previous marijuana use); concurrent or planned use of marijuana during the active study period are excluded. Positive urine drug screen (UDS) at screening due to prescribed stimulants will be reviewed on a case by case basis. 23. Cancer, or treatment for cancer, within the past 3 years (excluding fully treated and resolved basal cell carcinoma or squamous cell carcinoma). 24. History of any form of angioedema. 25. History of GI bleeding including hematochezia (blood in stool) or melena (black stool) of unknown etiology or that has not been evaluated. 26. Any history or conditions that may lead to a higher risk of clotting events and/or thrombocytopenia, including: 1. Familial coagulopathy or personal history of bleeding disorder or thrombosis 2. History of heparin-related thrombotic events, and/or receiving heparin treatments 3. History of autoimmune or inflammatory disease 4. Presence of any of the following conditions known to increase the risk of thrombosis within 6 months prior to screening: i. Recent surgery other than fully healed cesarean delivery or excision/ biopsy of cutaneous lesions ii. Immobility (confined to bed or wheelchair for 3 or more successive days) iii. Head trauma with loss of consciousness or documented brain injury iv. Receipt of anticoagulants for prophylaxis of thrombosis v. Recent clinically significant infection including hospitalization for COVID-19 related illness. 27. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the investigational product or interpretation of study results. 28. Study team member or first-degree relative of any study team member (inclusive of sponsor and site personnel involved in the study).
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental VXA-CoV2-3.1 |
Participants previously immunized against COVID-19 infection will be randomized to receive VXA-CoV2-3.1 tablet oral vaccine. |
|
|
Active Comparator COMIRNATY® |
Participants previously immunized against COVID-19 infection will be randomized to receive COMIRNATY® injectable COVID-19 vaccine. |
|
Recruiting Locations
Pinnacle Research Group
Anniston, Alabama 36207
Anniston, Alabama 36207
Core Clinical Trials - Central Alabama Research LLC
Birmingham, Alabama 35209-8401
Birmingham, Alabama 35209-8401
Coastal Clinical Research
Mobile, Alabama 36608
Mobile, Alabama 36608
Avacare - Lenzmeier Family Medicine
Glendale, Arizona 85308
Glendale, Arizona 85308
Desert Clinical Research
Mesa, Arizona 85213
Mesa, Arizona 85213
Velocity Clinical Research - MedPharmics - Phoenix
Phoenix, Arizona 85020
Phoenix, Arizona 85020
Foothills Research Center
Phoenix, Arizona 85044
Phoenix, Arizona 85044
Avacare (CCT) - Fiel Family & Sports Medicine
Tempe, Arizona 85283
Tempe, Arizona 85283
Baptist Health Center for Clinical Research - Little Rock
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
Elligo Health Research (BTC/ClinEdge) - Core Healthcare Group
Cerritos, California 90703
Cerritos, California 90703
Velocity Clinical Research - Chula Vista (eStudySite - Chula Vista)
Chula Vista, California 91911
Chula Vista, California 91911
Avacare - Benchmark Research - SOCAL-Colton
Colton, California 92324
Colton, California 92324
Altasciences Los Angeles (Formerly WCCT Global)
Cypress, California 90630
Cypress, California 90630
Ark Clinical Research - Fountain Valley, CA
Fountain Valley, California 92708
Fountain Valley, California 92708
Velocity Clinical Research - San Diego (eStudySite - La Mesa)
La Mesa, California 91942
La Mesa, California 91942
Ark Clinical Research - Long Beach, CA
Long Beach, California 90815
Long Beach, California 90815
Velocity Clinical Research (National Research Institute) - Panorama City
Los Angeles, California 90057
Los Angeles, California 90057
Northern California Research
Sacramento, California 95821
Sacramento, California 95821
Avacare - Benchmark Research - Sacramento
Sacramento, California 95864
Sacramento, California 95864
Velocity Clinical Research - Gardena
Santa Ana, California 92704
Santa Ana, California 92704
Elite Research Network (ERN) - Legacy Clinical Trials
Colorado Springs, Colorado 80909
Colorado Springs, Colorado 80909
Tekton Research - Fort Collins
Fort Collins, Colorado 80528
Fort Collins, Colorado 80528
Avacare - Critical Care, Pulmonary and Sleep Associates
Lakewood, Colorado 80228
Lakewood, Colorado 80228
Tekton Research - Colorado - Longmont
Longmont, Colorado 80501
Longmont, Colorado 80501
Paradigm Clinical Research - Wheat Ridge
Wheat Ridge, Colorado 80033
Wheat Ridge, Colorado 80033
Stamford Therapeutics Consortium
Stamford, Connecticut 06905
Stamford, Connecticut 06905
Chase Medical Research
Waterbury, Connecticut 06708
Waterbury, Connecticut 06708
Velocity Clinical Research - Washington DC
Washington, District of Columbia 20016
Washington, District of Columbia 20016
AMR - Miami (Clinical Research of South Florida)
Coral Gables, Florida 33134
Coral Gables, Florida 33134
Universal Axon Clinical Research
Doral, Florida 33166
Doral, Florida 33166
Velocity Clinical Research - New Smyrna Beach
Edgewater, Florida 32132
Edgewater, Florida 32132
Fleming Island Center For Clinical Research
Fleming Island, Florida 32003
Fleming Island, Florida 32003
AMR - Fort Myers - Clinical Physiology Associates
Fort Myers, Florida 33912
Fort Myers, Florida 33912
Velocity Clinical Research - Hallandale Beach (MD Clinical)
Hallandale Beach, Florida 33009
Hallandale Beach, Florida 33009
ENCORE - Nature Coast Clinical Research Inverness
Inverness, Florida 34452
Inverness, Florida 34452
ENCORE - Westside Center for Clinical Research
Jacksonville, Florida 32205
Jacksonville, Florida 32205
Jacksonville Center for Clinical Research
Jacksonville, Florida 32216
Jacksonville, Florida 32216
Headlands Research - JEM Research - Lake Worth
Lake Worth, Florida 33462
Lake Worth, Florida 33462
Accel Research Sites - Lakeland
Lakeland, Florida 33803
Lakeland, Florida 33803
Accel Research Sites (ARS) - St. Petersburg - Largo
Largo, Florida 33777
Largo, Florida 33777
Accel Research Sites - Maitland
Maitland, Florida 32751
Maitland, Florida 32751
K2 Medical Research - Maitland
Maitland, Florida 32751
Maitland, Florida 32751
SRA Trials LLC - Miami Clinical Trials at Suncoast Research Associates
Miami, Florida 33173
Miami, Florida 33173
Atlas Clinical Research - Suncoast Clinical Research - Pasco County
New Port Richey, Florida 34652
New Port Richey, Florida 34652
Biscayne Clinical Research
North Miami Beach, Florida 33169
North Miami Beach, Florida 33169
K2 Medical Research - South Orlando
Orlando, Florida 32806
Orlando, Florida 32806
Boca Raton Clinical Research (BRCR) Global - Weston
Plantation, Florida 33322
Plantation, Florida 33322
ENCORE - St. Johns Center for Clinical Research
Saint Augustine, Florida 32086
Saint Augustine, Florida 32086
IMA Clinical Research - St. Petersburg
Saint Petersburg, Florida 33704
Saint Petersburg, Florida 33704
hyperCORE - Centricity Research Columbus
Columbus, Georgia 31904
Columbus, Georgia 31904
Javara Research - Privia Medical Group Georgia
Fayetteville, Georgia 30214
Fayetteville, Georgia 30214
Privia Health - SouthCoast Health
Fayetteville, Georgia 30214
Fayetteville, Georgia 30214
Avacare (CCT) - Lifeline Primary Care
Lilburn, Georgia 30047
Lilburn, Georgia 30047
hyperCORE - Centricity Research (IACT Health) - Rincon
Rincon, Georgia 31326
Rincon, Georgia 31326
Velocity Clinical Research - Savannah
Savannah, Georgia 31406
Savannah, Georgia 31406
Velocity Clinical Research - Boise (Meridian)
Meridian, Idaho 83642
Meridian, Idaho 83642
IMA Clinical Research - Chicago
Chicago, Illinois 60602
Chicago, Illinois 60602
Accellacare - Duly Health and Care
Lombard, Illinois 60148
Lombard, Illinois 60148
Velocity Clinical Research - Valparaiso (Buynak Clinical Research)
Valparaiso, Indiana 46383
Valparaiso, Indiana 46383
Accellacare - McFarland Clinic
Ames, Iowa 50010
Ames, Iowa 50010
Velocity (Meridian) Clinical Research - Sioux City
Sioux City, Iowa 51106
Sioux City, Iowa 51106
AMR - El Dorado - Heartland Research Associates
El Dorado, Kansas 67042
El Dorado, Kansas 67042
Johnson County Clin-Trials
Lenexa, Kansas 66219
Lenexa, Kansas 66219
AMR - Newton (Heartland Research Associates)
Newton, Kansas 67114
Newton, Kansas 67114
AMR - Wichita West - Heartland Research Associates
Wichita, Kansas 67205
Wichita, Kansas 67205
AMR - Wichita East - Heartland Research Associates
Wichita, Kansas 67207
Wichita, Kansas 67207
AMR - Lexington (Central Kentucky Research Associates)
Lexington, Kentucky 40509
Lexington, Kentucky 40509
Velocity (Meridian) Clinical Research - Baton Rouge
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Avacare - Benchmark Research - New Orleans-North Shore
Covington, Louisiana 70433
Covington, Louisiana 70433
Velocity Clinical Research - MedPharmics - Covington
Covington, Louisiana 70433
Covington, Louisiana 70433
Boca Raton Clinical Research (BRCR) Global USA - New Orleans
Gretna, Louisiana 70053
Gretna, Louisiana 70053
Velocity Clinical Research - MedPharmics - Lafayette
Lafayette, Louisiana 70508
Lafayette, Louisiana 70508
Avacare - Benchmark Research - Metairie
Metairie, Louisiana 70006
Metairie, Louisiana 70006
AMR - New Orleans - Center for Clinical Research
New Orleans, Louisiana 70119
New Orleans, Louisiana 70119
Javara Research - Privia Medical Group Mid-Atlantic - Annapolis
Annapolis, Maryland 21401
Annapolis, Maryland 21401
Pharmaron
Baltimore, Maryland 21201
Baltimore, Maryland 21201
Avacare (CCT) - Advanced Primary and Geriatric Care
Rockville, Maryland 20850
Rockville, Maryland 20850
Velocity (Meridian) Clinical Research - Rockville
Rockville, Maryland 20854
Rockville, Maryland 20854
Javara Research - Mankato Clinic
Mankato, Minnesota 56001
Mankato, Minnesota 56001
Velocity Clinical Research - MedPharmics - Gulfport
Gulfport, Mississippi 39503
Gulfport, Mississippi 39503
Avacare (CCT) - Clay Platte Family Medicine Clinic
Kansas City, Missouri 64151
Kansas City, Missouri 64151
Avacare (CCT) - Skyline Medical Center
Elkhorn, Nebraska 68022
Elkhorn, Nebraska 68022
Velocity (Meridian) Clinical Research - Grand Island
Grand Island, Nebraska 68803
Grand Island, Nebraska 68803
Be Well Clinical Studies - Nebraska
Lincoln, Nebraska 68516
Lincoln, Nebraska 68516
Velocity (Meridian) Clinical Research - Omaha
Omaha, Nebraska 68134
Omaha, Nebraska 68134
hyperCORE - ActivMed Practices and Research - Portsmouth
Portsmouth, New Hampshire 03801
Portsmouth, New Hampshire 03801
DM Clinical Research - Jersey City
Jersey City, New Jersey 07306
Jersey City, New Jersey 07306
Velocity Clinical Research - Alburquerque
Albuquerque, New Mexico 87107
Albuquerque, New Mexico 87107
AXCES Research & Health - Santa Fe
Santa Fe, New Mexico 87505
Santa Fe, New Mexico 87505
IMA Clinical Research - Albany, Suite 202
Albany, New York 12205
Albany, New York 12205
Velocity Clinical Research - Syracuse
East Syracuse, New York 13057
East Syracuse, New York 13057
IMA Clinical Research - Manhattan
New York, New York 10036
New York, New York 10036
Atlas Clinical Research - Rochester Clinical Research
Rochester, New York 14609
Rochester, New York 14609
Cary Medical Group
Cary, North Carolina 27518
Cary, North Carolina 27518
Velocity Clinical Research - Durham
Durham, North Carolina 27701
Durham, North Carolina 27701
Accellacare - Hickory
Hickory, North Carolina 28601
Hickory, North Carolina 28601
Accellacare - Raleigh
Raleigh, North Carolina 27609
Raleigh, North Carolina 27609
Accellacare - Rocky Mount
Rocky Mount, North Carolina 27804
Rocky Mount, North Carolina 27804
Accellacare - Salisbury
Salisbury, North Carolina 28144
Salisbury, North Carolina 28144
Accellacare - Piedmont Healthcare
Statesville, North Carolina 28625
Statesville, North Carolina 28625
Accellacare - Tradd Court
Wilmington, North Carolina 28401
Wilmington, North Carolina 28401
Accellacare - Winston-Salem
Winston-Salem, North Carolina 27103
Winston-Salem, North Carolina 27103
Atrium Health Wake Forest Baptist - Comprehensive Cancer Center
Winston-Salem, North Carolina 27157
Winston-Salem, North Carolina 27157
Velocity Clinical Research - Cleveland (Rapid Medical Research)
Beachwood, Ohio 44122
Beachwood, Ohio 44122
CTI Clinical Research Center
Cincinnati, Ohio 45212
Cincinnati, Ohio 45212
Velocity Clinical Research - Cincinnati (New Horizons Clinical Research - Blue Ash)
Cincinnati, Ohio 45242
Cincinnati, Ohio 45242
Tekton Research - Oklahoma - Magnolia Court
Moore, Oklahoma 73160
Moore, Oklahoma 73160
Tekton Research - Delaware Pointe
Tulsa, Oklahoma 74137
Tulsa, Oklahoma 74137
Tekton Research - Oklahoma - Primary Health Partners
Yukon, Oklahoma 73099
Yukon, Oklahoma 73099
Velocity Clinical Research - Grants Pass
Grants Pass, Oregon 97527
Grants Pass, Oregon 97527
Avacare (CCT) - Hatboro Medical Associates
Hatboro, Pennsylvania 19040
Hatboro, Pennsylvania 19040
Atlas Clinical Research - Suburban Research Associates - Media Office
Media, Pennsylvania 19063
Media, Pennsylvania 19063
Velocity Clinical Research - Providence (East Greenwich)
East Greenwich, Rhode Island 02818
East Greenwich, Rhode Island 02818
Velocity Clinical Research - Anderson
Anderson, South Carolina 29621
Anderson, South Carolina 29621
Velocity Clinical Research - Charleston
Charleston, South Carolina 29414
Charleston, South Carolina 29414
Velocity Clinical Research - Columbia (VitaLink)
Columbia, South Carolina 29204
Columbia, South Carolina 29204
Accellacare - Charleston
Mount Pleasant, South Carolina 29464
Mount Pleasant, South Carolina 29464
Trial Management Associates - Myrtle Beach
Myrtle Beach, South Carolina 29572
Myrtle Beach, South Carolina 29572
hyperCORE International - Coastal Carolina Research Center
North Charleston, South Carolina 29405
North Charleston, South Carolina 29405
Velocity Clinical Research - Union (Vitalink)
Union, South Carolina 29379
Union, South Carolina 29379
Accellacare - PMG Research of Bristol
Bristol, Tennessee 37620
Bristol, Tennessee 37620
Alliance for Multispecialty Research (AMR) - Corporate
Knoxville, Tennessee 37909
Knoxville, Tennessee 37909
Accellacare of Knoxville
Knoxville, Tennessee 37912
Knoxville, Tennessee 37912
Velocity Clinical Research - Abilene
Abilene, Texas 79606
Abilene, Texas 79606
IMA Clinical Research - Austin
Austin, Texas 78745
Austin, Texas 78745
Tekton Research - Austin
Austin, Texas 78745
Austin, Texas 78745
Orion Clinical Research
Austin, Texas 78759
Austin, Texas 78759
Velocity Clinical Research - Austin
Austin, Texas 78759
Austin, Texas 78759
Tekton Research - Beaumont
Beaumont, Texas 77706
Beaumont, Texas 77706
PanAmerican Clinical Research - Brownsville, Levee Street
Brownsville, Texas 78520
Brownsville, Texas 78520
Cedar Health Research - Arlington/Euless
Euless, Texas 76040
Euless, Texas 76040
EmVenio Research - Fort Worth, TX
Fort Worth, Texas 76134
Fort Worth, Texas 76134
Avacare - Benchmark Research Fort Worth
Fort Worth, Texas 76135
Fort Worth, Texas 76135
DM Clinical Research - CyFair Clinical Research Center
Houston, Texas 77065
Houston, Texas 77065
Tekton Research - Fredericksburg Road
San Antonio, Texas 78229
San Antonio, Texas 78229
DM Clinical Research - Tomball - Multiple Specialties
Tomball, Texas 77375
Tomball, Texas 77375
Velocity Clinical Research - Waco (formerly: Impact Research Institute)
Waco, Texas 76710
Waco, Texas 76710
Avacare (CCT) - Ogden Clinic - Grand View
Roy, Utah 84067
Roy, Utah 84067
Avacare (CCT) - Olympus Family Medicine
Salt Lake City, Utah 84117
Salt Lake City, Utah 84117
South Ogden Family Medicine
South Ogden, Utah 84405
South Ogden, Utah 84405
Health Research of Hampton Roads
Newport News, Virginia 23606
Newport News, Virginia 23606
AMR - Norfolk (Clinical Research Associates of Tidewater)
Norfolk, Virginia 23502
Norfolk, Virginia 23502
Centricity Research (IACT Health) - Suffolk Primary Care
Suffolk, Virginia 23435
Suffolk, Virginia 23435
Velocity Clinical Research - Medford
Spokane, Washington 99204
Spokane, Washington 99204
Velocity Clinical Research - Spokane
Spokane, Washington 99204
Spokane, Washington 99204
More Details
- NCT ID
- NCT06672055
- Status
- Recruiting
- Sponsor
- Vaxart